S. 741 · 116th Congress
Cancer Drug Parity Act of 2019
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
SmithSponsor19 cosponsors · 9 D, 10 R
R
Moran
CM
D
Murphy
RW
R
Wicker
SB
D
Brown
LM
R
Murkowski
CH
R
Hyde-Smith
AK
D
Klobuchar
JB
R
Boozman
EM
D
Markey
RB
D
Blumenthal
SC
R
Collins
TB
D
Baldwin
KC
R
Cramer
MB
R
Blackburn
JM
D
Merkley
SC
R
Capito
SW
D
Whitehouse
DJ
D
Jones
RS
R
Scott3 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill requires health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications.
What it does: CRS summary · Introduced in Senate · Mar 12, 2019
Cancer Drug Parity Act of 2019
This bill requires health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration.
To comply with this requirement, health plans may not, with respect to anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Cancer Drug Parity Act of 2019
Latest action (Mar 12, 2019): Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Policy area: Health · Origin: Senate · Introduced: Mar 12, 2019
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.